Absci (ABSI) announced a collaboration with Oracle Cloud Infrastructure (ORCL) and AMD (AMD) to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large-scale molecular-dynamics simulations and end-to-end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD’s next generation Instinct MI355X GPUs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci Corp. Earnings Call: Strategic Gains Amid Challenges
- Promising Potential of AbSci’s ABS-201 Therapy for Androgenetic Alopecia: A Buy Recommendation
- Promising Developments and Strong Financial Position Bolster AbSci’s Growth Prospects
- AbSci’s Positive Outlook: Strong Financial Position and Promising ABS-101 Developments Support Buy Rating
- Absci Corporation Reports Q2 2025 Financial Results